Sells minimally invasive surgery, endoscopic and smoke-removal devices to surgeons and other healthcare professionals, as well as orthopedic surgery products.
10-K for FY2025, filed Feb 17, 2026CONMED Corporation was incorporated under the laws of the State of New York in 1970 and became a Delaware corporation in May 2020. CONMED…View ↗
We design, manufacture and globally distribute products which enable orthopedic surgeons to surgically address sports medicine injuries in…View ↗
Our advanced surgical product offering includes the leading clinical insufflation system (AirSeal®). AirSeal® includes the proprietary…View ↗
General-surgery buyers pay for products when they ship. Orthopedic products are also paid for at shipment; CONMED additionally earns a fee from MTF tied to its customer invoices for promoting sports medicine tissue, with services provided over time.
10-K for FY2025, filed Feb 17, 2026
10-K for FY2025, filed Feb 17, 2026
FY2025 revenue by product or service ↗$1.4B
10-K for FY2025, filed Feb 17, 2026
$1.4B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Orthopedic Surgery
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
42%
FY2022: 44%
|
Orthopedic Surgery, FY2025
$574.6M Sources
|
Sold outright |
|
General Surgery
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
58%
FY2022: 56%
|
General Surgery, FY2025
$800.1M Sources
|
Sold outright |
Hospitals, surgery centers and other healthcare institutions buy directly or through medical specialty distributors; internationally, local dealers and direct in-country sales teams serve customers. Some hospitals use independent medical device distributors for inventory management.
10-K for FY2025, filed Feb 17, 2026A significant portion of our products are distributed domestically directly to more than 6,000 hospitals, surgery centers and other…View ↗
Expanding our international presence is an important component of our long-term growth plan. Our products are sold in over 100 countries.…View ↗
A significant portion of our U.S. sales are to customers affiliated with GPOs, IDNs and other large national or regional accounts, as well…View ↗
Yes. It kept 3 cents of every revenue dollar as net income in FY2025 and turned 11 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 28, 2026
$19.8MView ↗
10-Q for Q3 FY2026, filed Oct 28, 2026
Open tableView ↗
8-K, filed Jul 29, 2026
Dollars in millions, except per share figures Percentages on a year-over-year basis, may not foot due to rounding Twelve Months Ending…View ↗
8-K, filed Jun 17, 2026
Largo, Fla. – June 17, 2026 – CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial…View ↗
Growing. Revenue grew 36% in 4 years, from $1B in FY2021 to $1.4B in FY2025, about 8% a year.
Gastroenterology product exit
The older report described a broad portfolio of gastroenterology products. The latest report says CONMED intends to exit the remaining gastroenterology products after ending its Gore biliary-device distribution agreement.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 17, 2026Our advanced endoscopic technologies offering includes a comprehensive line of therapeutic and diagnostic products used in gastroenterology…View ↗
Competes with Smith & Nephew, Arthrex, Stryker, Johnson & Johnson, Zimmer Biomet, Globus Medical, Treace Medical Concepts, Medtronic, Olympus, ERBE Elektromedizin, Applied Medical Resources, Boston Scientific, Cook Medical, Merit Medical, STERIS, Cantel Medical, Cardinal Health, and 3M
10-K for FY2025, filed Feb 17, 2026We design, manufacture and globally distribute products which enable orthopedic surgeons to surgically address sports medicine injuries in…View ↗
Loading...